Table 2.
Resistance-associated variants (RAVs) in 3 patients with virologic failure were analyzed by direct sequencing methods.
| Case | Times | NS3 | NS5A | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| V36 | T54 | Q80 | R155 | A156 | D168 | V170 | L31 | Q54 | Y93 | ||
| No.1 | Before Tx | - | - | - | - | - | - | - | - | - | - |
| Stopping Tx (1 week) |
- | - | - | - | - | - | - | - | - | - | |
| No.2 | Before Tx | - | - | - | - | - | - | V/I/M | - | - | - |
| Stopping Tx (2 weeks) |
- | - | - | - | - | - | - | - | - | - | |
| No.3 | Before Tx | - | - | - | - | - | - | - | - | - | - |
| VBT (8 weeks) | - | - | R | - | - | E | I | - | - | - | |
| 24 weeks after Tx | - | - | R | - | - | E | I | - | - | - | |
Tx, therapy; VBT, virologic breakthrough